Louis Fehrenbacher, MD, on Invasive Breast Cancer: Results From the NSABP B-47 Trial

2017 San Antonio Breast Cancer Symposium
Tweet this page

Louis Fehrenbacher, MD, of Kaiser Permanente, discusses study findings comparing adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel—or docetaxel and cyclophosphamide—with or without a year of trastuzumab in women with node-positive or high-risk node-negative disease (Abstract GS1-02).

Advertisement

Advertisement



Advertisement